Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam

  title={Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam},
  author={Taylor E. Savage and Jo Sourbron and Patricia L. Bruno and Lauren A. Skirvin and Emma Wolper and Christina J. Anagnos and Elizabeth A Thiele},
  journal={Epilepsy Research},

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics

It is necessary to investigate CBD safety, pharmacokinetics and interaction with other AEDs alongside performing double-blinded placebo-controlled trials to obtain conclusive data on its efficacy and safety in the most frequent epilepsies in children, not just in the epileptic encephalopathy.

Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials

The best clinical evidence to date is provided that CBD exerts therapeutic effects in patients with epilepsy that are independent of its interaction with CLB, and greater antiseizure effects, and a greater burden of adverse effects, are observed when CBD is combined withCLB.

Cannabinoids in the Treatment of Epilepsy: A Review

This review seeks to offer a fairly comprehensive description of the facets of cannabinoid therapy for refractory epilepsy and examines the interactions between cannabinoids and other conventional antiseizure medications.

Development of cannabidiol as a treatment for severe childhood epilepsies

The introduction of CBD as the medicine Epidiolex in the United States and as Epidyolex in the European Union as the first cannabis‐derived therapeutic for the treatment of seizures was underpinned by preclinical research performed at the University of Reading, which was awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019.

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.

  • C. E. Navarro
  • Medicine, Biology
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • 2022
The CBMF is a highly effective and safety therapy to treat adult patients with DRFE and the reduction in seizures frequency is maintained over time.

The long‐term efficacy of cannabidiol in the treatment of refractory epilepsy

The efficacy of CBD for a treatment period of up to 60 months is investigated to reduce seizures among patients with refractory epilepsies of various etiologies.

Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome

Combination of CLZ with CBD significantly reduced seizure duration compared to the vehicle or CLZ alone, but did not affect seizure severity, indicating potential additive actions ofCLZ and CBD on the duration of seizures.

Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome

The currently available data suggest that response to treatment with a highly purified, plant-derived CBD oil-based solution can be seen in patients across a broad range of epilepsy disorders and etiologies, and can provide preliminary support for additional research.



Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis

The aim of the study was to estimate the efficacy and safety of CBD as adjunctive treatment in patients with epilepsy using meta-analytical techniques.

Cannabidiol in patients with treatment-resistant epilepsy

Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy

Efficacy, safety and tolerability of CBD treatment were assessed through the evaluation of seizure frequency and reports of adverse effects, and data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile.

Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis

Adjunctive CBD resulted in a greater reduction in seizure frequency and a higher rate of AEs than placebo in patients with LGS presenting seizures uncontrolled by concomitant AEDs.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.